← board
HRTX
distress 5/10 · elevated risk$0.46-3%today-79% from 52w high
Revenue
pre-revenue
Liquidity
$26M
Runway
1.3 yrs
Shares 1y
+24%
Price & events
-68.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.2%
1D
-5.2%
1W
+8.4%
1M
-54.5%
3M
-68.0%
6M
-76.8%
1Y
-85.6%
2Y
-96.5%
5Y
-97.8%
All
Overview
- Market Cap
- $86.14M
- Volume
- 67.50K
- 52 Week Range
- $0.38 – $2.18
- Total Shares
- 189.28M
- Float Shares
- 135.44M
- Short %
- 27.28%
- % Held by Insiders
- 0.90%
- % Held by Institutions
- 82.20%
- RVOL
- 0.02x
- Beta
- 1.65
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-08-07Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-08-08partnershipPrivate placement of ~13.2M common shares and ~524k preferred shares for ~$27.7M.SEC 8-K
- 2025-08-08partnershipIssued $35M convertible senior unsecured promissory notes due 2031.SEC 8-K
- 2025-08-08partnershipExchange Agreement to exchange $150M Existing Notes for $25M equity and $125M cash repayment.SEC 8-K
- 2025-08-08partnershipEntered into Second Amendment to Loan Agreement increasing debt capacity to $150M and extending maturity to 2030.SEC 8-K
- 2025-08-08partnershipCooperation agreement with Rubric Capital Management regarding board composition.SEC 8-K
- 2025-05-06partnershipCINVANTI, APONVIE · Heron grants Mylan a license to market generic CINVANTI and APONVIE starting June 1, 2032.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $2 (+339% upside) · 1 analysts
- 2026-06-03HC Wainwright & Co.Buy
- 2026-06-03NeedhamBuy → Hold
- 2026-01-09HC Wainwright & Co.Buy
- 2025-08-08NeedhamBuy
- 2025-06-09HC Wainwright & Co.Buy
- 2025-04-11NeedhamBuy
Competitors
- none identified
Recent news
- 2026-06-26Heron Therapeutics, Inc. 8-K Filing: Nasdaq Listing Status, Company Details & Key SEC Disclosures (June 25, 2026) - Minichart
- 2026-06-25Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
- 2026-06-25Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price - Stock Titan
- 2026-06-16Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan - Stock Titan
- 2026-06-02Court rules CINVANTI patents invalid; Heron readies appeal - Stock Titan
- 2026-05-13Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX) - Stock Titan
- 2026-05-11Acute-care net revenue up 32% as Heron settles CINVANTI patent case - Stock Titan
- 2026-05-11Heron Therapeutics Reports Q1 2026 Results: 32% Acute Care Revenue Growth, Reaffirms 2026 Guidance - Minichart
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.